Excelse Bio — A New Paradigm in the Biologics Conversation

Innovative delivery for today’s biotechnology drugs

Excelse Bio, headquartered in Thousand Oaks, California, is focused on improved formulation and delivery of injectable biotechnology products to change therapy as we know it today.


It was founded by biologics experts in protein formulation from Amgen and other leading biotechnology firms. Our team of leading scientists have deep experience in high concentration formulation and are able to apply the EXCELSE™ technology to a variety of delicate biotechnology drugs.

Excelse Bio is a privately held company, an affiliate of Integrity Bio, Inc., a leader in biotechnology formulation services established in 2003. Excelse Bio has ongoing research studies with large biotechnology and biopharmaceutical partners.


Michael Reilly

Michael Reilly

Chief Executive Officer, co-founder

Michael has over 25 years of international leadership experience in marketing, business development, strategy, and finance at Amgen, Baxter, Sanofi, Sterling Drug, and Eastman Kodak. He continues to serve as VP of Business Development, Integrity Bio, a biotechnology formulation services firm affiliated with Excelse Bio.

Previously, Michael was Head of Strategy and member of the Senior Management Team at Baxter BioScience. He was the commercial lead for Amgen's acquisition of Immunex and its drug Enbrel, the largest in biotech history at $16B. As Global Commercial Leader at Amgen, he led denosumab (PROLIA, XGEVA) and several other Product Strategy Teams for Rheumatoid Arthritis, Alzheimer's, Parkinson's Disease and Cancer.

Michael earned a Master's degree from the Ross School of Business at the University of Michigan in Ann Arbor, and a Bachelor's degree in Molecular Biology from the University of California, Berkeley.

Byeong Chang

Byeong Chang

Chief Scientific Officer, co-founder

In 2003 Dr. Chang founded Integrity Bio, a biotechnology formulation services firm that has developed over 200 protein formulations for large and small firms. Integrity Bio is also the developer of Lyotip, a prefilled delivery system for lyophilized drugs.

Dr. Chang is widely recognized as an expert in the area of protein formulations and participated in more than 100 combined publications, presentations, patents, and invited seminar presentations. In addition to being President of Integrity Bio, he has 20 years of experience at Amgen, Synergen, Cetus, and Smithkline Beecham. At Amgen, Dr. Chang was Associate Director, Department of Pharmaceutics and Drug Delivery, where he served for 12 years.

Dr. Chang received his Ph.D. from University of Massachusetts, Amherst, and a Bachelor's degree from Seoul National University.